Edward J. Tanner
YOU?
Author Swipe
View article: Evaluation of a Quality-Improvement Initiative to Address Nutritional Anemia in Gynecologic Oncology
Evaluation of a Quality-Improvement Initiative to Address Nutritional Anemia in Gynecologic Oncology Open
OBJECTIVE: Anemia is common among patients with gynecologic cancers receiving systemic treatment and is associated with adverse outcomes. We describe a quality-improvement initiative designed to improve screening and treatment for nutritio…
View article: SOX9 drives a stem-like transcriptional state and platinum resistance in high-grade serous ovarian cancer
SOX9 drives a stem-like transcriptional state and platinum resistance in high-grade serous ovarian cancer Open
Chemotherapy resistance remains a formidable challenge to the treatment of high-grade serous ovarian cancer (HGSOC). The drug-tolerant cells may originate from a small population of inherently resistant cancer stem cells (CSCs) in primary …
View article: Supplementary Table S7 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Table S7 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Top TSGs upregulated in response to NTX-301.
View article: Supplementary Figure S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Figure S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
OC cells are highly sensitive to NTX301 treatment.
View article: Supplementary Material and Methods S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Material and Methods S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Supplementary Material and Methods
View article: Supplementary Table S4 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Table S4 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Primary antibody information
View article: Supplementary Table S8 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Table S8 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Supplemental Table S8. Top 30 gene with increased methylation level in OVCAR5 cells treated with NTX301 compared to DMSO.
View article: Supplementary Figure S3 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Figure S3 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
NTX-301 effects in OC cells
View article: Supplementary Figure S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Figure S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
OC cells are highly sensitive to NTX301 treatment.
View article: Supplementary Figure S2 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Figure S2 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
NTX301 induced transcriptome and methylome reprogramming in OC cells.
View article: Supplementary Figure S6 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Figure S6 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
NTX-301 monotherapy inhibits PDX tumor growth.
View article: Data from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Data from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Purpose:DNA methylation causes silencing of tumor-suppressor and differentiation-associated genes, being linked to chemoresistance. Previous studies demonstrated that hypomethylating agents (HMA) resensitize ovarian cancer to chemotherapy.…
View article: Supplementary Table S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Table S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Tumor characteristics
View article: Supplementary Figure S4 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Figure S4 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Effects of HMAs on HDAC expression.
View article: Supplementary Figure S5 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Figure S5 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
NTX301 inhibits OC tumor growth in vivo.
View article: Supplementary Table S2 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Table S2 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Primer sequences for selected genes in qRT-PCR analysis
View article: Supplementary Figure S4 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Figure S4 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Effects of HMAs on HDAC expression.
View article: Supplementary Table S9 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Table S9 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Top 30 gene with decreased methylation level in OVCAR5 cells treated with NTX301 compared to DMSO.
View article: Supplementary Figure S2 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Figure S2 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
NTX301 induced transcriptome and methylome reprogramming in OC cells.
View article: Supplementary Table S5 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Table S5 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Top 30 downregulated DEGs in OVCAR5 cells treated with NTX301 compared to DMSO.
View article: Supplementary Table S4 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Table S4 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Primary antibody information
View article: Data from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Data from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Purpose:DNA methylation causes silencing of tumor-suppressor and differentiation-associated genes, being linked to chemoresistance. Previous studies demonstrated that hypomethylating agents (HMA) resensitize ovarian cancer to chemotherapy.…
View article: Supplementary Table S7 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Table S7 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Top TSGs upregulated in response to NTX-301.
View article: Supplementary Table S3 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Table S3 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Primer sequences for H3K27Ac ChIP-qPCR
View article: Supplementary Figure S6 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Figure S6 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
NTX-301 monotherapy inhibits PDX tumor growth.
View article: Supplementary Table S2 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Table S2 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Primer sequences for selected genes in qRT-PCR analysis
View article: Supplementary Table S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Table S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Tumor characteristics
View article: Supplementary Figure S5 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Figure S5 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
NTX301 inhibits OC tumor growth in vivo.
View article: Supplementary Table S6 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Table S6 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Top 30 upregulated DEGs in OVCAR5 cells treated with NTX301 compared to DMSO. TSGs are bolded.
View article: Supplementary Table S8 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Supplementary Table S8 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer Open
Supplemental Table S8. Top 30 gene with increased methylation level in OVCAR5 cells treated with NTX301 compared to DMSO.